Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Abeona Therapeutics (ABEO) Research & Development (2016 - 2025)

Abeona Therapeutics (ABEO) has 15 years of Research & Development data on record, last reported at $4.2 million in Q3 2025.

  • For Q3 2025, Research & Development fell 52.85% year-over-year to $4.2 million; the TTM value through Sep 2025 reached $29.1 million, down 11.15%, while the annual FY2024 figure was $34.4 million, 10.51% up from the prior year.
  • Research & Development reached $4.2 million in Q3 2025 per ABEO's latest filing, down from $5.9 million in the prior quarter.
  • Across five years, Research & Development topped out at $12.8 million in Q4 2021 and bottomed at $4.2 million in Q3 2025.
  • Average Research & Development over 5 years is $8.1 million, with a median of $8.3 million recorded in 2021.
  • Peak YoY movement for Research & Development: skyrocketed 39.68% in 2021, then tumbled 52.85% in 2025.
  • A 5-year view of Research & Development shows it stood at $12.8 million in 2021, then plummeted by 51.01% to $6.3 million in 2022, then rose by 17.65% to $7.4 million in 2023, then grew by 21.89% to $9.0 million in 2024, then tumbled by 53.12% to $4.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $4.2 million in Q3 2025, $5.9 million in Q2 2025, and $9.9 million in Q1 2025.